Six newly Certified Centers join the organization's network of clinics and expand access to multidisciplinary care and research for people living with ALS. ALS, often called Lou Gehrig's disease, is a ...
Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166.
Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and neurological conditions, announced the company has ...
Pennington Biomedical’s Dr. Jeff Keller and Dr. Aron Culotta of Tulane to lead collaboration of AI researchers, neuroscientist and drug developers Answer ALS is proud to announce the launch of a ...
The UAB ALS Multidisciplinary Clinic has been designated a Certified Treatment Center of Excellence (CTCE) by the ALS Association, a recognition that underscores its commitment to providing the ...
Ochsner Neuroscience Institute is marking the 10-year anniversary of its Amyotrophic Lateral Sclerosis (ALS) Center, a recognized Center of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results